Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|August 20, 2020
MHRA to Resume On-Site Inspections in September 2020
Author(s)Pharmaceutical Technology Editors
The UK's MHRA will resume on-site risk based GxP inspections from September 2020.
Advertisement
The Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has announced it will resume on-site risk-based good practice (GxP) inspections in September 2020.
According to an August 11, 2020 press release, the agency specified that the inspection program will resume in September 2020 in line with a reduction in COVID-19 restrictions, and a scale-up to a full program of inspections is expected in October 2020. On-site inspections were suspended on March 20, 2020 as a result of COVID-19 social distancing and travel restriction requirements.
A combination of remote and on-site inspection approaches will be employed as COVID-19 restrictions are continuing to be eased, the agency stated in the press release. Guidance on what companies should expect in the event of an on-site inspection are available on the MHRA’s website. Any site/organization to be inspected will receive a minimum of 14 days prior notification so that planning to minimize COVID-19 risk can be performed.
Source:
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement